X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Phase 1 of pre-clinical development, clearly demonstrate that many of chosen bio-compounds have potential to exert beneficial effects that mitigate neurological deficits associated with many CNS disorders and mental health conditions.
Lead Product(s): Psilocybin-based Therapy
Therapeutic Area: Neurology Product Name: AKO002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Core One Labs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
The University of Barcelona, Faculty of Pharmacy and Food Sciences, Laboratory of Medicinal Chemistry, has been selected by Akome as the candidate, to provide technical guidance for the necessary in vitro studies of its proposed pharmaceutical psychedelic drug formulations.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Barcelona
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 25, 2022
Details:
Akome is in process of identifying Contract Research Organizations (CROs) to work with as it sets the development process of its novel AKO001 psychedelic drug formulation and its advancement for the treatment of stroke.
Lead Product(s): Dimethyltryptamine
Therapeutic Area: Neurology Product Name: AKO001
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2021
Details:
Currently Akome has 4 provisional matter of composition patents filed with the United States Patent and Trademark Office, one psilocybin-based, for addressing Alzheimer’s Disease; and one ketamine-based, for addressing depression.
Lead Product(s): Psilocybine,Plant bioactive compound
Therapeutic Area: Neurology Product Name: AKO002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Core One Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 04, 2021
Details:
The acquisition of Akome further positions the Company at the forefront of development of psychedelic drugs for neurological diseases and mental disorders.
Lead Product(s): Psychedelic drug
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Core One Labs
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
